Glaxo and Theravance announce positive Phase 3 results for COPD regimen

In two Phase 3 clinical trials, patients with chronic obstructive pulmonary disease (COPD) who received the anticholinergic Incruse Ellipta (umeclidinium 62.5 mcg) or umeclidinium 125 mcg (an unlicensed dose) in addition to Relvar/Breo Ellipta (fluticasone furoate/vilanterol "FF/VI"), an inhaled corticosteroid/long-acting beta2-agonist combination, achieved a statistically significant improvement in lung function (FEV1) compared to patients receiving FF/VI plus placebo reports GlaxoSmithKline (GSK) and commercial partner Theravance (THRX).

Both studies were 12-week multicenter, randomized, double-blinded placebo-controlled trials involving 1,238 patients with COPD. The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85.

The full results of the studies will be posted on and presented at a future scientific meeting.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs